per patient. Nonetheless, there is no consensus on the optimal regimen of TXA in TKA. Intravenous, intraarticular, oral, and combined administrations have been reported to achieve satisfactory outcome. [5] [6] [7] [8] The decision depends on the surgeon's preference and the cost. Although there are concerns about systemic use of TXA in increasing the risk of hypercoagulation and thromboembolic events, it was safe to use in most patients.
It is worth pointing out that the study by Goyal et al. 4 was a retrospective review of medical records. The TXA group was compared with the historical controls. The preoperative diagnosis and patients' co-morbidities were not clearly documented. The peri-operative care in terms of deep vein thrombosis prophylaxis, rehabilitation and discharge protocol was not standardised. Therefore, the evidence generated is not as strong as that from randomised controlled trials or meta-analyses.
